ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is BrightPath Biotherapeutics Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of -36.36% over the last 5 years
3
The company declared negative results in Dec'25 after flat results in Sep'25
- NET SALES(9M) At JPY 0.03 MM has Grown at -62.92%
- DEBT-EQUITY RATIO (HY) Highest at -84.99 %
- RAW MATERIAL COST(Y) Grown by 101.34% (YoY)
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -2.17% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is BrightPath Biotherapeutics Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
BrightPath Biotherapeutics Co., Ltd.
-2.17%
-0.23
118.42%
Japan Nikkei 225
85.83%
3.09
27.80%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-36.36%
EBIT Growth (5y)
4.96%
EBIT to Interest (avg)
-1,564.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.85
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.50
EV to EBIT
-7.38
EV to EBITDA
-7.38
EV to Capital Employed
57.61
EV to Sales
8924.17
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-780.30%
ROE (Latest)
-116.14%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at JPY -713.22 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 59.83 times
-21What is not working for the Company
NET SALES(9M)
At JPY 0.03 MM has Grown at -62.92%
DEBT-EQUITY RATIO
(HY)
Highest at -84.99 %
RAW MATERIAL COST(Y)
Grown by 101.34% (YoY
CASH AND EQV(HY)
Lowest at JPY 2,197 MM
OPERATING PROFIT(Q)
Lowest at JPY -492.02 MM
PRE-TAX PROFIT(Q)
Lowest at JPY -491.75 MM
NET PROFIT(Q)
Lowest at JPY -492.36 MM
EPS(Q)
Lowest at JPY -4.36
Here's what is working for BrightPath Biotherapeutics Co., Ltd.
Debtors Turnover Ratio
Highest at 59.83 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for BrightPath Biotherapeutics Co., Ltd.
Net Sales
At JPY 0.03 MM has Grown at -62.92%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (JPY MM)
Pre-Tax Profit
At JPY -491.75 MM has Fallen at -83.65%
over average net sales of the previous four periods of JPY -267.76 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (JPY MM)
Net Profit
At JPY -492.36 MM has Fallen at -83.51%
over average net sales of the previous four periods of JPY -268.3 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (JPY MM)
Debt-Equity Ratio
Highest at -84.99 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Operating Profit
Lowest at JPY -492.02 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (JPY MM)
Pre-Tax Profit
Lowest at JPY -491.75 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (JPY MM)
Net Profit
Lowest at JPY -492.36 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (JPY MM)
EPS
Lowest at JPY -4.36
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (JPY)
Cash and Eqv
Lowest at JPY 2,197 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 101.34% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
